Rudrapatna, Vivek A.
Ravindranath, Vignesh G.
Arneson, Douglas V.
Mosenia, Arman
Butte, Atul J.
Wang, Shan
Funding for this research was provided by:
National Center for Advancing Translational Sciences (UL1 TR001872, UL1 TR001872, UL1 TR001872, UL1 TR001872, UL1 TR001872, UL1 TR001872)
Division of Gastroenterology, University of California, San Francisco
Bakar Computational Health Sciences Institute, University of California, San Francisco
University of San Francisco
Article History
Received: 23 December 2022
Accepted: 16 August 2023
First Online: 3 October 2023
Declarations
:
: This study was approved in accordance with the Declaration of Helsinki and with the oversight of the UCSF IRB (#18–24588). This review board waived the need for participant consent given that the underlying data had already been deidentified by the owners of the raw data.
: Not applicable.
: VAR received grant support from Janssen Inc and Alnylam Inc for unrelated work during this study. DVA is currently an employee at Bristol Myers Squibb. AJB is a co-founder and consultant to Personalis and NuMedii; consultant to Mango Tree Corporation, and in the recent past, Samsung, 10 × Genomics, Helix, Pathway Genomics, and Verinata (Illumina); has served on paid advisory panels or boards for Geisinger Health, Regenstrief Institute, Gerson Lehman Group, AlphaSights, Covance, Novartis, Genentech, and Merck, and Roche; is a shareholder in Personalis and NuMedii; is a minor shareholder in Apple, Meta (Facebook), Alphabet (Google), Microsoft, Amazon, Snap, 10 × Genomics, Illumina, Regeneron, Sanofi, Pfizer, Royalty Pharma, Moderna, Sutro, Doximity, BioNtech, Invitae, Pacific Biosciences, Editas Medicine, Nuna Health, Assay Depot, and Vet24seven, and several other non-health related companies and mutual funds; and has received honoraria and travel reimbursement for invited talks from Johnson and Johnson, Roche, Genentech, Pfizer, Merck, Lilly, Takeda, Varian, Mars, Siemens, Optum, Abbott, Celgene, AstraZeneca, AbbVie, Westat, and many academic institutions, medical or disease specific foundations and associations, and health systems. Atul Butte receives royalty payments through Stanford University, for several patents and other disclosures licensed to NuMedii and Personalis. Atul Butte’s research has been funded by NIH, Peraton (as the prime on an NIH contract), Genentech, Johnson and Johnson, FDA, Robert Wood Johnson Foundation, Leon Lowenstein Foundation, Intervalien Foundation, Priscilla Chan and Mark Zuckerberg, the Barbara and Gerson Bakar Foundation, and in the recent past, the March of Dimes, Juvenile Diabetes Research Foundation, California Governor’s Office of Planning and Research, California Institute for Regenerative Medicine, L’Oreal, and Progenity. The authors have declared that no actual competing interests exist.